BioFire Diagnostics, Inc.

BioFire Diagnostics, Inc. specializes in innovative diagnostic solutions, focusing on syndromic infectious disease diagnostics through advanced multiplex PCR technology to enhance clinical decision-making and patient care. Founded in 1990 and headquartered in Salt Lake City, US, BioFire Diagnostics, Inc. develops advanced diagnostic products for infectious diseases.

In September 2013, the company was acquired by bioMérieux for USD 450 mn. The CEO, Kirk Ririe, leads the organization as it continues to focus on the diagnostics market. BioFire Diagnostics specializes in syndromic infectious disease diagnostics, with its core product being the BIOFIRE System. This advanced diagnostic platform utilizes multiplex PCR technology to provide rapid, accurate results for a range of pathogens, including viruses, bacteria, parasites, yeast, and antimicrobial resistance genes.

With the capability to deliver results in about one hour, the BIOFIRE System addresses critical needs in clinical settings, particularly for healthcare providers seeking to improve patient care and antibiotic stewardship. The product offerings primarily include the BIOFIRE FILMARRAY Panels, which cater to various clinical scenarios such as respiratory infections, blood culture identification, gastrointestinal issues, meningitis/encephalitis, pneumonia, and joint infections. BioFire Diagnostics serves a broad customer base that includes hospitals, clinical laboratories, and healthcare providers across multiple geographical markets, including North America, Europe, and Asia. The company’s revenue is primarily generated through the sales of its diagnostic products and systems.

Transactions typically occur through direct sales to healthcare providers and laboratories, with a focus on B2B relationships. The BIOFIRE System is offered as a capital purchase, with additional revenue streams derived from consumables associated with the diagnostic panels. Specific pricing structures for the BIOFIRE System and its associated panels are determined based on individual contracts with healthcare facilities, which may involve volume discounts or subscription models for ongoing supplies. The flagship BIOFIRE FILMARRAY Panels, recognized for their comprehensive testing capabilities, play a vital role in driving sales and enhancing customer loyalty within the clinical diagnostics market.

Following the acquisition by bioMérieux in September 2013, BioFire Diagnostics plans to leverage its resources for the expansion of its product offerings. The firm is focused on developing new diagnostic panels tailored to emerging infectious diseases, with anticipated releases aligned with market demands. Additionally, the company is exploring expansion into Asia-Pacific markets, targeting growth by 2025. The funds from the acquisition will support these product developments and market expansions.